|Articles|October 1, 2001
- Pharmaceutical Executive-10-01-2001
- Volume 0
- Issue 0
Oncology: EMEA Approval Lags
Author(s)Kevin Gopal
London-European cancer patients are losing out because current processes for reviewing treatments are "dire," says the Cancer Research Campaign.
Advertisement
Articles in this issue
about 24 years ago
National Crisis Supercedes Coverage Debateabout 24 years ago
PBMs: Merck-Medco in the Hot Seatabout 24 years ago
National Crisis Supercedes Coverage Debateabout 24 years ago
A Five-Year Forecast: Clear Seas Ahead?about 24 years ago
Weak Bones, Strong Marketabout 24 years ago
Approvals: Novartis’ Silver Liningabout 24 years ago
Pfizer and others Pitch Inabout 24 years ago
Illegal Sales in Indiaabout 24 years ago
Health Plan Premiums: Pharma Takes the Blameabout 24 years ago
Little Elan Becomes a Big DealNewsletter
Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on PharmExec
1
TrumpRx and the Dawn of Direct-to-Consumer Commercialization
2
Could DTC Programs Help Simplify the Drug-Pricing System?
3
Lilly Enters Definitive Agreement Acquiring Aderum Biotechnologies
4
AI Becomes Pharma’s New Operating System: Q&A with causaLens’ CEO and Co-Founder Darko Matovski
5
